{"schema_version":"secwatch.filing_event.v1","accession":"0001824293-23-000073","form_type":"8-K","ticker":"GRI","cik":"0001824293","company_name":"GRI Bio, Inc.","filed_at":"2023-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.908744+00:00","generated_at":"2026-06-16T21:37:09.753137+00:00","sec_items":["1.01","8.01","2.01","3.03","4.01","5.01","5.02","5.03","3.02","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vallon Pharmaceuticals completes reverse merger with GRI Bio; combined entity renamed GRI Bio, Inc.","bullets":["Merger closed April 21, 2023; former GRI stockholders own ~85% of combined company, Vallon stockholders ~15%.","Vallon effected 1-for-30 reverse stock split; ticker changes from VLON to GRI on April 24, 2023.","New board appointed: W. Marc Hertz as CEO, David Szekeres as Chair; prior directors except David Baker resigned.","EisnerAmper dismissed as auditor; Sadler, Gibb & Associates engaged for fiscal year 2023.","GRI issued Exchange Warrants for 421,589 shares at $14.73; Equity Warrants to be issued May 8, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001824293-23-000073","json":"https://secwatch.observer/filing/0001824293-23-000073.json","markdown":"https://secwatch.observer/filing/0001824293-23-000073.md","text":"https://secwatch.observer/filing/0001824293-23-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/val-20230421.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T21:37:09.753137+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c4d7701d385863e5089374924698d80a970a6b5c","claim":"GRI Bio, Inc. dismissed EisnerAmper LLP as its auditor.","evidence_excerpt":"the Audit Committee of the Board approved the dismissal of EisnerAmper LLP (“EisnerAmper”) as the Company’s independent registered public accounting firm","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"dismissal"},{"label":"Auditor","value":"EisnerAmper LLP"}],"fact_type":"auditor_change"},{"claim_id":"c9ece7242bd164e64ac20d8e9f58cc8b2883c170","claim":"GRI Bio, Inc. engaged Sadler, Gibb & Associates LLC as its auditor.","evidence_excerpt":"engaged Sadler as the independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2023","evidence_source":"SEC 8-K Item 4.01/4.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.9,"family_label":"Auditor Changes","details":[{"label":"Action","value":"engagement"},{"label":"Auditor","value":"Sadler, Gibb & Associates LLC"}],"fact_type":"auditor_change"},{"claim_id":"011df6b04c","claim":"Vipin Kumar Chaturvedi was appointed as Chief Scientific Officer at GRI Bio, Inc..","evidence_excerpt":"Vipin Kumar Chaturvedi, Ph.D. as the Company’s Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"0a53ae364e","claim":"David Szekeres was appointed as Chairperson of the Board at GRI Bio, Inc..","evidence_excerpt":"Mr. Szekeres was appointed as the Chairperson of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"16234ee368","claim":"David Baker resigned as other_named_officer at GRI Bio, Inc..","evidence_excerpt":"In connection with the resignation for David Baker","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.8,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"22c82da5a6","claim":"Leanne Kelly was appointed as Chief Financial Officer at GRI Bio, Inc..","evidence_excerpt":"Leanne Kelly as the Company’s Chief Financial Officer (principal financial and accounting officer)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"311d1d5e43","claim":"David Szekeres was appointed as Director at GRI Bio, Inc..","evidence_excerpt":"the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"32576b307e","claim":"Camilla V. Simpson was appointed as Director at GRI Bio, Inc..","evidence_excerpt":"the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"42ea0b1d74","claim":"Albert Agro was appointed as Chief Medical Officer at GRI Bio, Inc..","evidence_excerpt":"Albert Agro, Ph.D. as the Company's Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"84bd2ea51c","claim":"Roelof Rongen was appointed as Director at GRI Bio, Inc..","evidence_excerpt":"the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a82e79c795","claim":"W. Marc Hertz was appointed as Chief Executive Officer at GRI Bio, Inc..","evidence_excerpt":"the Board appointed W. Marc Hertz, Ph.D. as the Company’s Chief Executive Officer (principal executive officer)","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"e95094929b","claim":"W. Marc Hertz was appointed as Director at GRI Bio, Inc..","evidence_excerpt":"the Board appointed W. Marc Hertz, Ph.D., David Szekeres, Roelof Rongen and Camilla V. Simpson, M.Sc. to the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"db6dfb5971f7f938b9b34312b1b00ab8f2d5014e","claim":"GRI Bio, Inc.: Amended the certificate of incorporation to effect a 1-for-30 reverse stock split (effective 2023-04-21).","evidence_excerpt":"On April 21, 2023, prior to the Effective Time, the Company filed the Stock Split Amendment with the Secretary of State of the State of Delaware to effect the Reverse Split.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-04-21"}],"fact_type":"governance_change"},{"claim_id":"f19b5afd96e313a6f7c37e78ff117a6174ff000e","claim":"GRI Bio, Inc. underwent a change of control involving GRI Operations, Inc. (closed 2023-04-21).","evidence_excerpt":"Merger Sub was merged with and into GRI (the \"Merger\"), with GRI surviving the Merger as a wholly owned subsidiary of the Company.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1824293/000182429323000073/0001824293-23-000073-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"GRI Operations, Inc."},{"label":"Closing","value":"2023-04-21"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}